Davita Downtown Dallas Dialysis is a medicare approved dialysis facility center in Dallas, Texas and it has 16 dialysis stations. It is located in Dallas county at 3515 Swiss Ave, Suite A, Dallas, TX, 75204. You can reach out to the office of Davita Downtown Dallas Dialysis at (214) 828-2280. This dialysis clinic is managed and/or owned by Davita. Davita Downtown Dallas Dialysis has the following ownership type - Profit. It was first certified by medicare in December, 2006. The medicare id for this facility is 672553 and it accepts patients under medicare ESRD program.
| Name | Davita Downtown Dallas Dialysis |
|---|---|
| Location | 3515 Swiss Ave, Suite A, Dallas, Texas |
| No. of Dialysis Stations | 16 |
| Medicare ID | 672553 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 3515 Swiss Ave, Suite A, Dallas, Texas, 75204 | |
| (214) 828-2280 | |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
| NPI Number | 1285048801 |
| Organization Name | Home For Texas Dfw |
| Doing Business As | Renal Treatment Centers-southeast Lp |
| Address | 3515 Swiss Ave Dallas, Texas, 75204 |
| Phone Number | (469) 334-0216 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
| NPI Number | 1669492260 |
| Organization Name | Davita Downtown Dallas Dialysis |
| Doing Business As | Renal Treatment Centers Southeast Lp |
| Address | 3515 Swiss Ave Dallas, Texas, 75204 |
| Phone Number | (214) 828-2280 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 60% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 13% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 27% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 57% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 14% |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 60% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 16% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 24% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 12% |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 79% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 21% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 69% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 12% |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 53 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 92 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 882 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita Downtown Dallas Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 96 |
| Hypercalcemia patient months | 940 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 97 |
| Patients with Serumphosphor less than 3.5 mg/dL | 5 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 39 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 21 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 84 |
| Patient months included in arterial venous fistula and catheter summaries | 692 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 59 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 73 |
| Hospitalization Rate in facility | 205.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 338 |
| Hospitalization Rate: Lower Confidence Limit | 128.2 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita Downtown Dallas Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 28 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 40.6 |
| Readmission Rate: Lower Confidence Limit | 16.9 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita Downtown Dallas Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.31 (As Expected) |
| SIR: Upper Confidence Limit | 2.72 |
| SIR: Lower Confidence Limit | .53 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita Downtown Dallas Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 64 |
| Transfusion Rate in facility | 38.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 92.5 |
| Transfusion Rate: Lower Confidence Limit | 17.6 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita Downtown Dallas Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 375 |
| Mortality Rate in facility | 23 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 30.7 |
| Mortality Rate: Lower Confidence Limit | 16.9 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago
Fresenius Medical Care Pd Services Of Dallas Location: 8700 North Stemmons, Dallas, Texas, 75247 Phone: (214) 905-8075 |
South Oak Cliff Dialysis Center Location: 740 Wynnewood Shop Ctr, Dallas, Texas, 75224 Phone: (214) 943-7065 |
News Archive
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Australia has the potential to eradicate hepatitis C in the next 10–15 years, according to Associate Professor Simone Strasser, gastroenterologist at Royal Prince Alfred Hospital in Sydney.
Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
Young girls with mental illness are three times more likely to become teenage parents than those without a major mental illness, according to a first-of-its-kind study by researchers at the Institute for Clinical Evaluative Sciences and Women's College Hospital.
› Verified 4 days ago